Susquehanna International Group
SYRE icon

Susquehanna International Group’s Spyre Therapeutics SYRE Stock Holding History

Susquehanna International Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$661K Buy
13,100
+5,300
+68% +$200K ﹤0.01% 8944
2025
Q4 		$256K Buy
+7,800
New +$204K ﹤0.01% 10317
2025
Q2 		– Sell
-23,200
Closed -$374K – 13694
2025
Q1 		$374K Buy
+23,200
New +$483K ﹤0.01% 9568

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Susquehanna International Group's SYRE Position: Q1 2026 in Review

Susquehanna International Group increased its Spyre Therapeutics (SYRE) stake by 374% in Q1 2026, buying an estimated $861K and bringing the position to 28,962 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #6960.

Susquehanna International Group first reported a position in SYRE in Q2 2017 and has held it in 17 quarters since. The position peaked at $3.85M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Susquehanna International Group held 28,962 shares of Spyre Therapeutics worth $1.46M as of Q1 2026.
  • Susquehanna International Group bought 22,851 Spyre Therapeutics shares in Q1 2026, an estimated $861K.
  • Spyre Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6960 holding.
  • Susquehanna International Group first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 17 quarters since.
  • Susquehanna International Group's Spyre Therapeutics position peaked at $3.85M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.